🔮 Today's Oracle Signal — July 20, 2026
Full federal rescheduling of psilocybin/MDMA does NOT pass Congress this session (by Jan 2027).
71% confidence
Legislation · Resolves 2027-01-16
Will MDMA Be FDA-Approved for PTSD? (2026–2027 Odds)
A tracked, falsifiable answer from OOTWOracle · updated July 20, 2026
Not in 2026, and most likely not before 2027. The Oracle currently puts it at 97% that no psychedelic drug gets full US approval before August 2026 (resolves 2026-08-16). MDMA-assisted therapy for PTSD is the furthest-along psychedelic program, but the FDA has signalled it wants additional confirmatory evidence before approval.
MDMA-assisted therapy for post-traumatic stress disorder is the most advanced psychedelic treatment in the regulatory pipeline. But 'most advanced' is not the same as 'approved': the FDA has pushed for more evidence on durability and trial design, which resets the clock. Here is the honest current read on timing.
Current odds on this question
| Oracle odds | Prediction (falsifiable) | Resolves |
|---|
| 97% | No psychedelic drug gets full US approval before August 2026 | 2026-08-16 |
| 90% | MDMA and psilocybin stay in the most restricted drug category through mid-2026 | 2026-08-16 |
| 90% | Psilocybin and MDMA stay in the most restricted drug category through October 2026 | 2026-10-11 |
| 85% | US drug agency won't move to reschedule psilocybin or MDMA soon | 2026-08-19 |
| 85% | Psilocybin and MDMA won't get full US drug approval in all of 2026 | 2026-12-31 |
Every row is a public, dated, falsifiable prediction — scored against a written resolution rule when the date arrives. Methodology & hit-rate: the track record.
Frequently asked
Is MDMA FDA-approved for PTSD?
No. As of July 20, 2026, MDMA has no FDA approval and remains Schedule I. It is in the regulatory pipeline but not cleared.
When could MDMA be approved?
The Oracle's odds favor no approval in 2026; a realistic path runs through a resubmission with new confirmatory data, pushing a decision toward 2027 or later.
Will MDMA be rescheduled?
Rescheduling out of Schedule I generally follows FDA approval of a specific product, so it is not expected ahead of an approval decision.
Why not just approve it now?
The FDA has raised questions about long-term durability and functional-unblinding in the trials; addressing those typically requires additional controlled data.